Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Issue 2 (31st October 2012)
- Record Type:
- Journal Article
- Title:
- Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Issue 2 (31st October 2012)
- Main Title:
- Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial
- Authors:
- Diletti, Roberto
Farooq, Vasim
Girasis, Chrysafios
Bourantas, Christos
Onuma, Yoshinobu
Heo, Jung Ho
Gogas, Bill D
van Geuns, Robert-Jan
Regar, Evelyn
de Bruyne, Bernard
Dudek, Dariusz
Thuesen, Leif
Chevalier, Bernard
McClean, Dougal
Windecker, Stephan
Whitbourn, Robert J
Smits, Pieter
Koolen, Jacques
Meredith, Ian
Li, Xiaolin
Miquel-Hebert, Karine
Veldhof, Susan
Garcia-Garcia, Hector M
Ormiston, John A
Serruys, Patrick W - Abstract:
- Abstract : Background: The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implantation. Methods: In ABSORB Cohort B Trial, out of the total study population (101 patients), 45 patients were assigned to undergo 6-month and 2-year angiographic follow-up (Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). The pre-reference vessel diameter (RVD) was <2.5 mm (small-vessel group) in 41 patients (41 lesions) and ≥2.5 mm (large-vessel group) in 60 patients (61 lesions). Outcomes were compared according to pre-RVD. Results: At 2-year angiographic follow-up no differences in late lumen loss (0.29±0.16 mm vs 0.25±0.22 mm, p=0.4391), and in-segment binary restenosis (5.3% vs 5.3% p=1.0000) were demonstrated between groups. In the small-vessel group, intravascular ultrasound analysis showed a significant increase in vessel area (12.25±3.47 mm 2 vs 13.09±3.38 mm 2 p=0.0015), scaffold area (5.76±0.96 mm 2 vs 6.41±1.30 mm 2 p=0.0008) and lumen area (5.71±0.98 mm 2 vs 6.20±1.27 mm 2 p=0.0155) between 6-months and 2-year follow-up. No differences in plaque composition were reported between groups at either time point. At 2-year clinical follow-up, no differences in ischaemia-driven major adverse cardiac events (7.3% vs 10.2%, p=0.7335), myocardial infarction (4.9% vs 1.7%,Abstract : Background: The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implantation. Methods: In ABSORB Cohort B Trial, out of the total study population (101 patients), 45 patients were assigned to undergo 6-month and 2-year angiographic follow-up (Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). The pre-reference vessel diameter (RVD) was <2.5 mm (small-vessel group) in 41 patients (41 lesions) and ≥2.5 mm (large-vessel group) in 60 patients (61 lesions). Outcomes were compared according to pre-RVD. Results: At 2-year angiographic follow-up no differences in late lumen loss (0.29±0.16 mm vs 0.25±0.22 mm, p=0.4391), and in-segment binary restenosis (5.3% vs 5.3% p=1.0000) were demonstrated between groups. In the small-vessel group, intravascular ultrasound analysis showed a significant increase in vessel area (12.25±3.47 mm 2 vs 13.09±3.38 mm 2 p=0.0015), scaffold area (5.76±0.96 mm 2 vs 6.41±1.30 mm 2 p=0.0008) and lumen area (5.71±0.98 mm 2 vs 6.20±1.27 mm 2 p=0.0155) between 6-months and 2-year follow-up. No differences in plaque composition were reported between groups at either time point. At 2-year clinical follow-up, no differences in ischaemia-driven major adverse cardiac events (7.3% vs 10.2%, p=0.7335), myocardial infarction (4.9% vs 1.7%, p=0.5662) or ischaemia-driven target lesion revascularisation (2.4% vs 8.5%, p=0.3962) were reported between small and large vessels. No deaths or scaffold thrombosis were observed. Conclusions: Similar clinical and angiographic outcomes at 2-year follow-up were reported in small and large vessel groups. A significant late lumen enlargement and positive vessel remodelling were observed in small vessels. … (more)
- Is Part Of:
- Heart. Volume 99:Issue 2(2013)
- Journal:
- Heart
- Issue:
- Volume 99:Issue 2(2013)
- Issue Display:
- Volume 99, Issue 2 (2013)
- Year:
- 2013
- Volume:
- 99
- Issue:
- 2
- Issue Sort Value:
- 2013-0099-0002-0000
- Page Start:
- 98
- Page End:
- 105
- Publication Date:
- 2012-10-31
- Subjects:
- Coronary Artery Disease
Heart -- Diseases -- Treatment -- Periodicals
Cardiology -- Periodicals
616.12 - Journal URLs:
- http://www.bmj.com/archive ↗
http://heart.bmj.com ↗
http://www.heartjnl.com ↗ - DOI:
- 10.1136/heartjnl-2012-302598 ↗
- Languages:
- English
- ISSNs:
- 1355-6037
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19726.xml